trending Market Intelligence /marketintelligence/en/news-insights/trending/iQ0qCL47OqeGXTZBS7J2cw2 content esgSubNav
In This List

'Oncology is back' says GSK exec; 'video game' from PureTech targets ADHD


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

'Oncology is back' says GSK exec; 'video game' from PureTech targets ADHD

Here are the editors' top picks for the week ended Dec. 15.

'Oncology is back' at GlaxoSmithKline, says cancer R&D head

With an experimental multiple myeloma treatment and a pipeline of early stage immunotherapy assets, GlaxoSmithKline plc is ready to re-enter the cancer ring, says Axel Hoos, senior vice president of oncology research and development.

PureTech's Akili says 'video game' is digital medicine for ADHD

A novel approach for attention deficit and hyperactivity disorder may soon offer a treatment regimen that is more akin to a video game than a drug but still manages to control symptoms without any side effects.

Transparency key to making medicines more affordable, experts tell Senate panel

Making prescription drugs more affordable in the U.S. may hinge on whether biopharmaceutical companies can be compelled — either on their own volition or under congressional mandate — to be more transparent, witnesses told lawmakers.

Congress again ponders drug pricing, but makes no commitment on actions

The head of the House Energy and Commerce Committee told members of the health panel, who heard from 10 witnesses during a three-hour hearing, it was their charge to tackle drug pricing, but he made no commitment for putting legislation on the table.

CDC director's financial ties impede her ability to lead agency, senator says

Financial ties to various industries are impeding the head of the Centers for Disease Control and Prevention from doing her job, Democrat Sen. Patty Murray of Washington, ranking member on two Senate committees, charged.

Gilead, Novartis, Juno likely to compete on access, tolerance of CAR-T therapies

Researchers presented data on therapies from the three contenders at the American Society of Hematology conference in Atlanta, showing small differences in safety and specificity could be the big markers as to which company will edge out others.

Roche, BioMarin hemophilia therapies show long-term bleeding relief potential

Roche Holding AG and BioMarin Pharmaceutical Inc.'s hemophilia A therapies aim to eliminate bleeding events entirely, significantly changing the sometimes daily treatment regimens for severe disease.

CAR-T race gets crowded at hematology meeting

This week, gene therapies from Novartis AG, Gilead Sciences Inc., and Juno Therapeutics, Inc. took center stage at the American Society of Hematology conference in Atlanta.